Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment

被引:34
|
作者
Cacciapaglia, Fabio [1 ]
Anelli, Maria Grazia [1 ]
Rinaldi, Angela [1 ]
Fornaro, Marco [1 ]
Lopalco, Giuseppe [1 ]
Scioscia, Crescenzio [1 ]
Lapadula, Giovanni [1 ]
Iannone, Florenzo [1 ]
机构
[1] Univ Bari Aldo Moro, Rheumatol Unit, Dept Emergence Med & Transplantat DETO, I-70124 Bari, Italy
关键词
CARDIOVASCULAR EVENTS; DENSITY-LIPOPROTEIN; AMERICAN-COLLEGE; RISK; DISEASE; LDL; INFLAMMATION; BLOCKADE; THERAPY; ADALIMUMAB;
D O I
10.1155/2018/2453265
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Rheumatoid arthritis (RA) patients are at high risk of cardiovascular (CV) events, and the chronic inflammatory state may generate quantitative and qualitative changes in lipoprotein fractions. The anti-IL-6 receptor tocilizumab (TCZ), even if effective in inflammation and joint damage prevention, determined significant alterations to RA patients' lipid levels in randomized controlled trials, but real-world data are lacking. We evaluated the changes in lipid fraction levels and disease activity in a longitudinal cohort of RA patients on long-term treatment with tocilizumab (TCZ) in a community setting. We retrospectively selected 40 naive-biologic RA patients on treatment with intravenous TCZ compared to 20 RA patients on methotrexate treatment as the control group. Total cholesterol (Tot-Chol), low-density lipoproteins (LDL), high-density lipoprotein (HDL), and triglyceride (TG) levels were measured at the baseline and at 12, 24, and 52 weeks thereafter. At the same points, 28-joint disease activity score (DAS28), clinical disease activity index (CDAI), and EULAR clinical responses were also assessed. During the first 24 weeks, we observed in TCZ-treated patients a progressive statistically significant (p < 0.001) increase in Tot-Chol, LDL, HDL, and TG, which returned close to the baseline at 52 weeks. But no changes in the lipid-related CV risk indices Tot-Chol/HDL and LDL/HDL ratios and the atherogenic index (log(10) TG/HDL) were detectable. Notably, we observed a statistically significant negative correlation between changes in lipid fractions and DAS28 or CDAI. The prolonged treatment with TCZ was associated to a transient increase in cholesterol's fractions during the first 6 months of treatment, with inverse correlation to disease activity, but with no impact on surrogate lipid indices of atherogenic risk. These findings may aid clinicians in interpreting the RA patient's lipid profile in daily clinical practice.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Long-Term Tolerability of Tocilizumab for the Treatment of Rheumatoid Arthritis
    Hishitani, Yoshihiro
    Hirano, Toru
    Shima, Yoshihito
    Ogata, Atsushi
    Narazaki, Masashi
    Hagihara, Keisuke
    Tanaka, Toshio
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S877 - S877
  • [2] LONG-TERM TOCILIZUMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS IN DAILY CLINICAL PRACTICE
    Ono, Y.
    Hirano, Y.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1296 - 1296
  • [3] LONG-TERM SAFETY OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS (RA) PATIENTS (PTS)
    van Vollenhoven, Ronald
    Scali, Juan
    Curtis, Jeffrey R.
    Krasnow, Joel
    Vernon, Emma
    Alten, Rieke
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 1087 - 1087
  • [4] TOCILIZUMAB: ANALYSIS OF LONG-TERM EFFICACY AND SAFETY IN RHEUMATOID ARTHRITIS PATIENTS
    Chalmeta Verdejo, I.
    Gonzalez Puig, L.
    Labrador Sanchez, E.
    Feced Olmos, C. M.
    Grau Garcia, E.
    Ivorra Cortes, J.
    Martinez Cordellat, I.
    Negueroles Albuixech, R.
    Nunez-Cornejo Piquer, C.
    Ortiz Sanjuan, F. M.
    Valero Sanz, J. L.
    Arevalo Ruales, K.
    Alcaniz Escandell, C.
    Roman Ivorra, J. A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1049 - 1049
  • [5] TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: LONG-TERM EFFICACY FOR UP TO 3.5 YEARS
    Smolen, J. S.
    Gomez-Reino, J. J.
    Davies, C.
    Alecock, E.
    Rubbert-Roth, A.
    Emery, P.
    [J]. RHEUMATOLOGY, 2010, 49 : I110 - I111
  • [6] AN INTERIM ANALYSIS OF LONG-TERM EXTENSION TRIALS OF TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
    van Vollenhoven, R. F.
    Smolen, J. S.
    Tony, H. P.
    Codding, C.
    Keystone, E. C.
    Woodworth, T.
    Alecock, E.
    Alten, R.
    [J]. RHEUMATOLOGY, 2009, 48 : I86 - I87
  • [7] Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis following a Mean Treatment Duration of 3.9 Years
    Haraoui, Boulos
    Sebba, Anthony
    Rubbert-Roth, Andrea
    Scali, Juan
    Alten, Rieke
    Kremer, Joel
    Pitts, Laura
    Vernon, Emma
    van Vollenhoven, Ronald
    Genovese, Mark
    [J]. JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1508 - 1508
  • [8] Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis and a Mean Treatment Duration of 3.7 Years.
    Genovese, Mark C.
    Sebba, Anthony
    Rubbert-Roth, Andrea
    Jose Scali, Juan
    Alten, Rieke
    Kremer, Joel M.
    Pitts, Laura
    Vernon, Emma
    van Vollenhoven, Ronald F.
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S700 - S701
  • [9] LONG-TERM SAFETY OF TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS FOLLOWING A MEAN TREATMENT DURATION OF 3.9 YEARS
    Genovese, M.
    Sebba, A.
    Rubbert-Roth, A.
    Scali, J.
    Alten, R.
    Kremer, J.
    Pitts, L.
    Vernon, E.
    van Vollenhoven, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 461 - 461
  • [10] LONG-TERM SAFETY OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS CLINICAL TRIALS
    Taylor, A.
    Nash, P.
    Hall, S.
    Jones, G.
    Youssef, P.
    Porter-Brown, B.
    Thompson, L.
    Genovese, M.
    [J]. INTERNAL MEDICINE JOURNAL, 2012, 42 : 14 - 14